Cargando…

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma

BACKGROUND: Glioblastoma (GBM) is the most common and most malignant primary brain cancer in adults. Despite multimodality treatment, the prognosis is still poor. Therefore, further work is urgently required to discover novel therapeutic strategies for GBM treatment. METHODS: The synergistic effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Wei, Wang, Baocheng, Mao, Weiwei, Wang, Jiajia, Zhao, Yang, Li, Qifeng, Zhang, Chenran, Tang, Yujie, Ma, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167847/ https://www.ncbi.nlm.nih.gov/pubmed/30285808 http://dx.doi.org/10.1186/s13046-018-0916-y

Ejemplares similares

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation
por: Rampazzo, Elena, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells
por: Pastorino, Olga, et al.
Publicado: (2019)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor
por: Gurbani, Saumya S, et al.
Publicado: (2020)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors
por: MacTavish, Heather, et al.
Publicado: (2010)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
por: Pratap, Uday P, et al.
Publicado: (2021)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
por: Tu, Bin, et al.
Publicado: (2020)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Wang, Hao, et al.
Publicado: (2021)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis
por: Wang, Changjun, et al.
Publicado: (2022)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
por: Xiao, Weiwei, et al.
Publicado: (2013)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
por: Chen, Danqi, et al.
Publicado: (2016)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

The effect of histone deacetylase inhibitors on AHSP expression
por: Okhovat, Mohammad Ali, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_091ncajorf4mnheacqmjcutor5